Searched for
PHARMACEUTICAL INTERMEDIARIES
These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsGiven the state of the market these days, it would be wise to be selective. Not only in terms of stocks, but also in terms of sectors. For ...- Time to be selectively bullish again? 5 small-cap stocks from different sectors with upside potential of up to 29%The conditions that created the worst 18 months for small-caps are starting to ease. The US-Iran war is moving towards settlement. Crude pr...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsThe latest escalation in the US-Iran war means that crude oil price is back as a risk for India. Although we are in a market already strugg...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsAs far as India is concerned, the biggest pain point from the US-Iran war in the Gulf region has been the spike in the prices of not only o...
- Why smallcap funds are still a buy: A long-term strategy from Aditya KhemaniSmallcap valuations seem high but underlying fundamentals have improved. Aditya Khemani of Invesco Mutual Fund sees this as a structural sh...
- Delius Pharma gets regulatory approval to import Ceftriaxone API from ChinaDelius Pharmaceuticals has secured approval from the CDSCO to import Ceftriaxone Sodium API from China's Guangxi Kelun Pharmaceutical. This...
- Exploring the Growth Potential of the Indian Pharmaceutical SectorThe Indian pharmaceutical sector is poised for significant growth, driven by favorable trade agreements and increasing global demand for ge...
- CCI clears Rs 13,630-cr Mankind Pharma-Bharat Serums Vaccines dealThe Competition Commission of India has approved Mankind Pharma's Rs 13,630 crore acquisition of Bharat Serums and Vaccines. This acquisiti...
- Specialty chemical startup Scimplify raises $9.5 million from Omnivore, othersScimplify to use the fresh capital to enhance research and development (R&D) capabilities and enter new markets. According to the company t...
- PLI scheme to attract Rs 3-4 lakh cr investments over 4 yrs; pvt sector capex may accelerate: IcraProduction-Linked Incentive (PLI) scheme is projected to draw investments worth Rs 3-4 lakh crore over four years, creating 2 lakh jobs. Ic...
- RP-Sanjiv Goenka, Bain Capital, Dorf Ketal in race to buy AquapharmAquapharm is a specialty chemical manufacturer and offers a range of products from phosphonates to pharmaceutical intermediaries. It deals ...
- CCI clears deal involving Sekhmet Pharmaventures, Optimus DrugsIn a tweet on Friday, the watchdog said it has approved acquisition of majority shareholding in Optimus Drugs by Sekhmet Pharmaventures as ...
- Coronavirus outbreak in China may affect Indian industries: GoyalCommerce and Industry Minister Piyush Goyal said that the closure of factories in China may affect Indian industries, which import componen...
- Frequent FDA inspections slow down Indian pharma exports, says GV PrasadGV Prasad, Chairman, CII National Committee on Pharmaceuticals said that everybody should up their game in terms of quality, systems, disci...
- GSP, medical devices, steel tariffs high on agendaAt least 7-8 officials from the US administration, including assistant US trade representative Mark Linscott, will be in New Delhi for the ...
- Aarti Industries bags Rs 4,000cr agro-chemical supply contractAs per the contract, the company will supply high value agro-chemical intermediary for use in herbicides over a period of 10 years.
- Telangana to set up Pharma City near HyderabadThe proposed park will have components and related activities with regard to antibiotics, synthetic drugs, vitamins, vaccines, drug formula...
- Telangana to set up 'Pharma City' near HyderabadTSIIC shall send detailed project proposal (DPR) to the government on modalities for implementation and execution of project.
- Watch: HealthKart looks to raise $30 million in Series CWatch how Prashant Tandon and Sameer Maheshwari started HealthKart and the startup's plans to raise Series C funding to propel growth.
- Solvay's sourcing from Dishman to cross Rs 100 crSolvay Pharmaceuticals BV the $11bn pharmaceutical major has consistently increased its sourcing from the Ahmedabad-based Dishman Pharmaceu...
Load More
